1. Immobilized Recombinant Human FGL1 Protein (rp146027) at 0.5 μg/mL can bind Recombinant Human LAG-3 Protein (rp176292) with the EC50 of 36.43 ng/mL. 2. Immobilized Recombinant Human LAG-3 Protein (rp176292) at 1.0 μg/mL can bind Relatlimab (anti-LAG-3/CD223) (Ab169321) with the EC50 of 41.53 ng/mL.
Protein Function： LAG-3 (Lymphocyte activation gene-3), designated CD223, is a 70 kDa type I transmembrane protein that is a member of the immunoglobulin superfamily (IgSF). LAG-3 shares approximately 20% amino acid sequence homology with CD4, but has similar structure and binds to MHC class II with higher affinity, providing negative regulation of T cell receptor signaling. Human LAG-3 cDNA encodes 525 amino acids (aa) that include a 28 aa signal sequence, a 422 aa extracellular domain (ECD) with four Ig-like domains, a transmembrane region and a highly charged cytoplasmic region. Within the ECD, human LAG-3 shares sequence identity with mouse, rat, porcine, and bovine LAG-3. LAG-3 is expressed on activated CD4+ and CD8+ T cells, NK cells, and plasmacytoid dendritic cells (pDC), but not on resting T cells. LAG-3 on activated CD4+CD25+ Treg cells plays a role in their suppressive activity. LAG-3 limits the expansion of activated T cells and pDC in response to selected stimuli. A soluble 54 kDa form, sLAG-3, can be shed by metalloproteinases ADAM10 and TACE/ADAM17. While monomeric sLAG-3 itself may be inactive, shedding allows for normal T cell activation by removing negative regulation. Binding of a homodimerized sLAG-3/Ig fusion protein to MHC class II molecules induces maturation of immature DC, and secretion of cytokines such as IFN-gamma and TNF-alpha by type 1 cytotoxic CD8+ T cells and NK cells. sLAG-3/Ig has been used as a potential adjuvant to stimulate a cytotoxic anti-cancer immune response. In mice, deletion of LAG-3 and another negative regulator, PD-1, facilitates anti-cancer response but also blocks self-tolerance and increases susceptibility to autoimmune diseases. In humans, antibody-mediated down regulation of LAG-3 and PD-1 allows more effective control of chronic malaria, while in NOD (non obese diabetic) mice, deletion of LAG-3 alone accelerates diabetes. LAG-3 is an immune checkpoint protein that modulates T-cell activation and homeostasis and is a promising target for cancer immunotherapy.
1. Immobilized Recombinant Human FGL1 Protein (rp146027) at 0.5 μg/mL can bind Recombinant Human LAG-3 Protein (rp176292) with the EC50 of 36.43 ng/mL. 2. Immobilized Recombinant Human LAG-3 Protein (rp176292) at 1.0 μg/mL can bind Relatlimab (anti-LAG-3/CD223) (Ab169321) with the EC50 of 41.53 ng/mL.
57.5 kDa, under reducing condition; 52.3 kDa, under non-reducing condition
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, pH 7.4
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.1 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
在 -20°C 下可保存 1 年。避免冷冻/解冻循环。
图片
Recombinant Human LAG-3 Protein (rp176292) - Binding Activity Immobilized Recombinant Human FGL1 Protein (rp146027) at 0.5 μg/mL can bind Recombinant Human LAG-3 Protein (rp176292) with the EC₅₀ of 36.43 ng/mL.
Recombinant Human LAG-3 Protein (rp176292) - ELISA Immobilized Recombinant Human LAG-3 Protein (rp176292) at 1.0 μg/mL can bind Relatlimab (anti-LAG-3/CD223) (Ab169321) with the EC₅₀ of 41.53 ng/mL.
Recombinant Human LAG-3 Protein (rp176292) - SDS-PAGE 3 μg/lane of Recombinant Human LAG-3 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 57.5 kDa under reducing conditions and 52.3 kDa under non-reducing conditions.
ZJ24F0707676
危险品化学品经营许可证（带存储）